New drug cocktail shows promise for aggressive breast cancer
NCT ID NCT03742102
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 25 times
Summary
This study tests whether combining the immunotherapy drug durvalumab with other cancer treatments (with or without chemotherapy) can help control metastatic triple-negative breast cancer in people who haven't had prior treatment for advanced disease. About 243 women with advanced or metastatic TNBC will receive different drug combinations to see how well they work and what side effects occur. The goal is to shrink tumors and delay progression, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Tucson, Arizona, 85715, United States
-
Research Site
Columbia, Maryland, 21044, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
Grand Rapids, Michigan, 49503, United States
-
Research Site
St Louis, Missouri, 63110, United States
-
Research Site
Dallas, Texas, 75246, United States
-
Research Site
Williamsburg, Virginia, 23188, United States
-
Research Site
Kelowna, British Columbia, V1Y 5L3, Canada
-
Research Site
London, Ontario, N6A 4L6, Canada
-
Research Site
Greenfield Park, Quebec, J4V 2H1, Canada
-
Research Site
Montreal, Quebec, H4A 3J1, Canada
-
Research Site
Gdansk, 80-952, Poland
-
Research Site
Krakow, 31-501, Poland
-
Research Site
Lublin, 20-090, Poland
-
Research Site
Opole, 45-060, Poland
-
Research Site
Rzeszów, 35-021, Poland
-
Research Site
Warsaw, 02-781, Poland
-
Research Site
Warsaw, 04-141, Poland
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Kaohsiung City, 80756, Taiwan
-
Research Site
Taichung, 40447, Taiwan
-
Research Site
Tainan, 70403, Taiwan
-
Research Site
Taipei, 10002, Taiwan
-
Research Site
Taipei, 112, Taiwan
-
Research Site
Taoyuan, 333, Taiwan
-
Research Site
Cambridge, CB2 0QQ, United Kingdom
-
Research Site
London, EC1M 6BQ, United Kingdom
-
Research Site
Manchester, M20 4BX, United Kingdom
-
Research Site
Oxford, OX3 7LE, United Kingdom
Conditions
Explore the condition pages connected to this study.